ESR2 and advanced heart failure: In line with our findings, Iorga et al. showed that DPN treatment, a selective Erβ agonist, in mice with advanced heart failure (HF) significantly reduces the LOX-1 mRNA expression in the ventricles as compared to untreated HF mice [94].